Goldman Sachs logo
Goldman Sachs

May 21, 2026

ConvaTec Plc YTD Growth and FY26 Guidance Update

Single Stock ReportEquitiesHealth Care

ConvaTec reported 4-month organic growth of 4.8% (ex-InnovaMatrix), which was slightly below expectations, but the company reiterated its FY26 guidance.

Key Takeaways

  • 1.Management reiterated FY26 guidance of 5-7% organic growth (excluding InnovaMatrix) and >23% adjusted EBIT margins.
  • 2.Year-to-date organic growth of +4.8% is considered 'a little light' compared to consensus expectations of +2.8% including InnovaMatrix.
  • 3.InnovaMatrix created a -300bps headwind to group organic growth due to structural changes in the US skin substitutes market.

Table of Contents

  • By division...
  • Valuation methodology
  • Key downside risks
  • GS Forecast
  • Disclosure Appendix
  • Ratings, coverage universe and related definitions

Document Preview

Page 1 of 5
Page 1 of ConvaTec Plc YTD Growth and FY26 Guidance Update
Subscribe for full access

Access the Full Report

Get unlimited access to institutional research reports with a 14-day free trial.

Authors

Richard Felton, CFALauren MitchellVisakh Subramaniam

Securities

CTEC.L

Themes

MedTech Growth PhasingUS Skin Substitutes Market Volatility

Regions

EuropeLatin AmericaAsia PacificUnited KingdomUnited States